Health Policy – Page 2 – Talk Bio

Actionable Insights Powered by AI

Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected

9 months ago talkbio0Tagged biotech industry, Changing, Drug Industry, Health Policy, M&A activity, regulatory environment, Transplant Registry Unified Management Program, United States Food and Drug Administration

Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

10 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry

10 months ago talkbio0Tagged Administration occupational activities, Biopharma, CHARGE Syndrome, Health Policy, Industry, nomination, RFK Jr., Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration

Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy

11 months ago talkbio0Tagged Dosage Forms, drug discount program, Health Policy, HRSA, Johnson & Johnson, Study models

340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing

Medicare Drug Price Negotiation Program Upheld in Court, Defeating Boehringer Ingelheim’s Challenge

1 year ago talkbio0Tagged Boehringer, Drug Industry, Health Policy, Ingelheim, Legal, Medicare, Negotiation Program

Medicare, drug pricing, negotiation program, Boehringer Ingelheim, legal challenge, pharmaceutical industry, healthcare policy